Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.

Are you looking for our logo? You can download our logo and get information about how to use it on our sharing page

Articles with the topic: featured

Harnessing the power of viruses to treat Huntington's disease

Harnessing the power of viruses to treat Huntington's disease

Leora Fox on February 03, 2016

New therapies for disorders like Huntington’s disease are on the way, but getting the drugs to enter brain cells can be a major challenge. A group of scientists has redesigned and tested a harmless virus that can efficiently deliver a 'gene silencing' message throughout the brain in mice, much further than naturally occurring viruses can reach. What's more, it can be given with a simple injection into the blood, offering great potential for research in gene silencing research and beyond.

Liftoff: First humans treated with gene silencing drugs for HD!

Liftoff: First humans treated with gene silencing drugs for HD!

Dr Jeff Carroll on October 22, 2015

Today brings news that the first Huntington's Disease patients have been successfully dosed with gene silencing drugs targeting the HD gene. These brave volunteers are the first HD patients to ever be treated with drugs designed to attack HD at its root cause, a treatment approach with huge potential. What about this news has us so excited?

Huge study reveals new 'genetic modifiers' of Huntington's disease

Huge study reveals new 'genetic modifiers' of Huntington's disease

Dr Jeff Carroll on July 31, 2015

Even though every patient with Huntington's Disease has a mutation in the same gene, the age at which HD patients develop symptoms varies widely. A global consortium of HD researchers has just published a landmark study of genetic differences between people that might explain some of that variability, producing some tantalizing new targets for drug discovery efforts.

Switching it up: variety in the HD gene affects symptom onset

Switching it up: variety in the HD gene affects symptom onset

Melissa Christianson on May 29, 2015

Just like it is difficult to predict exactly when a storm will hit, predicting when Huntington’s disease symptoms will arise for any particular person is hard to do. However, new research suggests that tiny changes in the on switch of the Huntington’s gene affect symptom onset – and may provide important information in the search for Huntington’s therapies.

Positive results announced for re-worked tetrabenazine drug in Huntington's disease

Positive results announced for re-worked tetrabenazine drug in Huntington's disease

Dr Jeff Carroll on December 22, 2014

Auspex Pharmaceuticals just announced the results of two clinical trials known as 'First-HD' and 'Arc-HD'. These trials were designed to test a modified version of the approved Huntington's disease drug tetrabenazine, which reduces unwanted movements. The results reveal that Auspex's drug has some advantages compared to tetrabenazine for treating excessive movements in HD.

Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015

Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015

Leora Fox on November 04, 2014

A new clinical trial just announced for 2015 aims to test a “huntingtin lowering” therapy, called an antisense oligonucleotide (ASO), that attacks mutant huntingtin directly. We’re extremely excited—it’s the first-ever human HD trial to fight HD at the root of the problem, and has shown great promise in animal models. What’s the scoop?

Largest creatine clinical trial for Huntington's disease halted after 'futility' analysis

Largest creatine clinical trial for Huntington's disease halted after 'futility' analysis

Dr Ed Wild on October 29, 2014

CREST-E, the largest clinical trial of the dietary supplement creatine, has been terminated early because an early analysis of the results to date showed there was no realistic chance it could show positive results. This provides compelling evidence that creatine doesn't slow down progression in Huntington's disease patients.

EuroBuzz 2014: day three

EuroBuzz 2014: day three

Dr Ed Wild on September 21, 2014

Our final report from the European HD Network meeting. For the first time, video of many presentations, including our 'EuroBuzz' sessions will be made available online shortly.

EuroBuzz 2014: day two

EuroBuzz 2014: day two

Dr Jeff Carroll on September 20, 2014

Here's Ed and Jeff's live Twitter report from the second day of the EHDN 2014 meeting. Our final report will be tomorrow, and we'll be uploading video of our onstage roundup sessions soon.